Profile
Prof Darren Lim is Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore and Professor, Duke-NUS Medical School. His research interests are in nasopharyngeal, lung, thyroid, and head and neck squamous cancers with focus on clinical trials and biological correlates.
Professional Appointments and Committee Memberships
- Professor, Academic Clinical Program (Oncology), Duke-NUS Medical School Singapore
- Senior Principal Investigator, Institute of Molecular and Cell Biology, A*STAR
- Director, Research, SingHealth Lung Disease Centre
- Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore
- International Association for the Study of Lung Cancer, Member
- European Society of Medical Oncology, Member
- Singapore Society of Oncology, Member
- Academy of Medicine Singapore, Fellow
View More +
Awards
- 2024 Ministry of Health Clinician-Scientist (CSA-SI) Award
- 2023 Master Clinical Trialist Development Award
- 2023 National Distinguished Senior Clinician Award
- 2019 Ministry of Health Clinician-Scientist Individual Research Grant (CS-IRG) Award
- 2017 Ministry of Health National Clinician Scientist Award
- 2013 Outstanding Clinician Researcher Award (Special Mention), GCEO Excellence Awards, SingHealth Excellence Awards
- 2012 Ministry of Health National Clinician Scientist Award
- 2004 Ministry of Health Manpower Development Award
View More +
Research Interests
- Clinical trials
- Nasopharyngeal cancer
- Lung cancer
- Head and Neck cancer
View More +
Publications
- Zhang X, Yan J, Lei Q, Neo J, Tan SH, Shu X, Huang L, Long B, Xie Y, Wang F, Wang Y, Tu H, Wang C, Zhang L, Yang J, Zhang J, Liu H,
Lim DWT, Chua MLK, Sui JD, Wang Y. A Randomized, Multicenter, Phase 2 Trial of Camrelizumab With or Without Metastasis-directed Stereotactic Body Radiation Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2024 Oct 23:S0360-3016(24)03512-0. doi: 10.1016/j.ijrobp.2024.10.019. Epub ahead of print. JIF: 6.4
- Chen Y, Zhang L, Wu X, Sun X, Sundah NR, Wong CY, Natalia A, Tam JKC,
Lim DW, Chowbay B, Ang BT, Tang C, Loh TP, Shao H. Magnetic augmentation through multi-gradient coupling enables direct and programmable profiling of circulating biomarkers. Nat Commun. 2024 Sep 27;15(1):8410. doi: 10.1038/s41467-024-52754-z. JIF: 14.7
- Saw SPL, Low YF, Lai GGY, Chan LL, Wong WKY, Tsui G, Chen OH, Seet AOL, Tan WC, Tan AC, Chan JWK, Teh YL, Tan WL, Ng QS, Ang MK, Kanesvaran R,
Lim DWT, Tan DSW, Mok TSK, Li MSC. Real-world out-comes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimer-tinib in advanced EGFR-mutated NSCLC. Lung Cancer. 2024 Jul;193:107856. doi: 10.1016/j.lungcan.2024.107856. Epub 2024 Jun 15. JIF: 4.5 6
- Ou SI, Le X, Nagasaka M, Reungwetwattana T, Ahn MJ,
Lim DWT, … et al. Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Muta-tions in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey. Lung Cancer (Auckl). 2024 Jun 22;15:87-114. doi: 10.2147/LCTT.S463429. JIF: 4.5
- Huang CY, Jiang N, Shen M, Lai GG, Tan AC, Jain A, Saw SP, Ang MK, Ng QS,
Lim DW, Kanesvaran R, Tan EH, Tan WL, Ong BH, Chua KL, Anantham D, Takano AM, Lim KH, Tam WL, Sim NL, Skanderup AJ, Tan DS, Rozen SG. Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced Mutations. Cancer Res. 2024 Jun 14;84(12):2009-2020. doi: 10.1158/0008-5472.CAN-23-2551. JIF: 12.5
- Tan AC, Lai GGY, Saw SPL, Chua KLM, Takano A, Ong BH, Koh TPT, Jain A, Tan WL, Ng QS, Kanesvaran R, Rajasekaran T, Kalashnikova E, Renner D, Sudhaman S, Malhotra M, Sethi H, Liu MC, Aleshin A,
Lim WT, Tan EH, Skanderup AJ, Ang MK, Tan DSW. Detection of circulating tumor DNA with ultradeep sequenc-ing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer. Cancer. 2024 May 15;130(10):1758-1765. doi: 10.1002/cncr.35263. Epub 2024 Feb 29. JIF: 6.2
- Ma BBY,
Lim DWT. Does 'B' stand for 'benefit'? Decoding the B-cell neighborhood in head and neck can-cer for predicting therapeutic response to PD-1 inhibitors. Ann Oncol. 2024 Apr;35(4):335-337. doi: 10.1016/j.annonc.2024.01.010. Epub 2024 Feb 9. JIF: 56.7
- Paz-Ares L, Goto Y,
Wan-Teck Lim D, ...et al. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial. Lung Cancer. 2024 Mar;189:107451. doi: 10.1016/j.lungcan.2023.107451. Epub 2024 Jan 16. JIF: 5.3
- Leong SY, Lok WW, Goh KY, Ong HB, Tay HM, Su C, Kong F, Upadya M, Wang W, Radnaa E, Menon R, Dao M, Dalan R, Suresh S,
Lim DW, Hou HW. High-Throughput Microfluidic Extraction of Platelet-free Plasma for MicroRNA and Extracellular Vesicle Analysis. ACS Nano. 2024 Feb 27;18(8):6623-6637. doi: 10.1021/acsnano.3c12862. Epub 2024 Feb 13. JIF: 17.1
- Guo Y, Nakashima T, Cho BC,
Lim DW, …, Stylianou C, Spiteri C, Porceddu S. Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary con-sensus in Asia-Pacific. Oral Oncol. 2024 Jan;148:106657. doi: 10.1016/j.oraloncology.2023.106657. Epub 2023 Dec 15. JIF: 4.8
- Neo J, Yip PL, Ong EHW, …, Ang MK, Tan SH,
Lim DWT, Chua MLK. Longitudinal post-radiotherapy plas-ma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carci-noma. Oral Oncol. 2024 Jan;148:106655. doi: 10.1016/j.oraloncology.2023.106655. Epub 2023 Dec 5. JIF: 4.8
- Tan JSH, Tay TKY, Ong EHW, Fehlings M, Tan DS, Sukma NB, Chen EX, Sng JH, Yip CSP, Lim KH,
Lim DW, Iyer NG, Hwang JSG, Chua MLK, Ang MK. Combinatorial Hypofractionated Radiotherapy and Pembroli-zumab in Anaplastic Thyroid Cancer. Eur Thyroid J. 2024 Jan 1;13(1):e230144. doi: 10.1530/ETJ-23-0144. Epub ahead of print. JIF: 4.7
-
Lim, D.WT., Kao, HF., Suteja, L. et al. Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 block-ade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma. Nat Commun 14, 2781 (2023). JIF: 17.694
- SPL Saw, WP Ng, S Zhou, ... WT Lim, R Kanesvaran, QS Ng, A Jain, WL Tan, T Rajasekeran, JWK Chan, YL The, M Pang, JC Yeo, A Takano, BH Ong, EH Tan, SH Tan, AJ Skanderup, DSW Tan. PD-L1 score as a prog-nostic biomarker in Asian early-stage EGFR-mutated lung cancer. European Journal of Cancer 2023, 178, 139-149. JIF 10.002
- Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT,…et al. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Naso-pharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA. 2023 Nov 28;330(20):1961-1970. doi: 10.1001/jama.2023.20181. JIF 120.7
View More +
Research Trials
- 20230153: Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects with methylthioadenosine phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), 2024
- BGB-LC-201: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unre-sectable, or Metastatic Non-Small Cell Lung Cancer, 2023
- BO42777: A Phase I-III, Multicenter Study Evaluating The Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer, 2022
- HERTHENA–Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Plati-num-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Recep-tor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy, 2022
- B7461039: Lorlatinib (PF-06463922) Continuation Protocol: An Open-label, Single-arm Continuation Study for Participants with ALK-positive or ROS1-positive Non-small Cell Lung Cancer (NSCLC) Continu-ing from Pfizer Sponsored Lorlatinib Clinical Studies, 2022
- HERTHENA-Lung01-U31402-A-U201: A Phase 2 Randomized Open-Label Study of U3-1402 in Subjects with Previously Treated Metastatic or Unresectable EGFR mutant Non-Small Cell Lung Cancer (NSCLC), 2021
- GO41767: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etopo-side Plus Atezolizumab With or Without Tiragolumab (anti-TIGIT Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02), 2020
- TPX-0005-01: A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harbor-ing ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1), 2017
- A phase II, open-label, randomized, controlled study of PDR001 in patients with moderately undifferen-tiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment, 2016
- A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (Ascend-7), 2015
- A phase III, open-label, multicenter, randomized study evaluating the efficacy and safety of MPDL3280A (Anti-PDL1 Antibody) in combination with carboplatin+paclitaxel or MPDL3280A in combina-tion with carboplatin+nab-paclitaxel versus carboplatin+nab-paclitaxel in chemotherapy-naive patients with stage IV squamous non-small cell lung cancer, 2015
- A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive- Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy (Dlim), 2015
View More +
